https://www.yiliao.com/index.php?action=history&feed=atom&title=%E8%8D%AF%E7%89%A9%E8%80%90%E8%8D%AF%E6%80%A7
药物耐药性 - 版本历史
2026-04-09T23:05:15Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E8%8D%AF%E7%89%A9%E8%80%90%E8%8D%AF%E6%80%A7&diff=316444&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-02-04T14:44:11Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>药物耐药性</strong>（Drug Resistance）是抗肿瘤治疗失败的主要原因，指肿瘤细胞对原本有效的治疗药物产生不敏感或抵抗的现象。根据发生时间，可分为<strong>原发性耐药</strong>（Intrinsic Resistance，治疗前即存在）和<strong>获得性耐药</strong>（Acquired Resistance，治疗初期有效，随后失效）。<br />
<br>耐药性的产生是肿瘤<strong>异质性</strong>（Heterogeneity）和治疗压力筛选共同作用的结果。其机制极度复杂，包括药物靶点的二次突变（如 EGFR T790M）、旁路信号的代偿性激活（如 [[矛盾性激活]]）、药物泵出增加以及细胞表型转化（如腺癌转化为小细胞癌）。克服耐药性是目前开发新一代靶向药物（如三代 TKI）和联合疗法（Combo）的核心驱动力。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Drug Resistance</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">抗肿瘤药物耐药 (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="width: 100px; height: 100px; background-color: #e2e8f0; border-radius: 50%; margin: 0 auto; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em;"><br />
<span style="font-size: 2em;">🛡️</span><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">治疗逃逸与防御</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">主要分类</th><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">原发性</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">Intrinsic (先天存在)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">获得性</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">Acquired (后天进化)</td><br />
</tr><br />
<br />
<tr><br />
<th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">核心机制</th><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">靶点改变</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;">二次突变 / 扩增</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">通路旁路</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #16a34a;">MET / HER2 激活</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569;">药物泵出</th><br />
<td style="padding: 6px 12px; color: #0f172a;">ABC 转运蛋白 (P-gp)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：肿瘤的“进化论”</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
耐药性的出现是达尔文进化论在微观层面的完美体现。在靶向药物的选择压力下，由于基因组的不稳定性，极少数具有生存优势的克隆会存活并扩增。<br />
</p><br />
<br />
<div style="background-color: #f0f9ff; border-left: 5px solid #1e40af; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>1. 守门人突变 (Gatekeeper Mutations)：</strong> 药物靶点蛋白的 ATP 结合口袋发生微小突变，阻止药物结合但不影响酶活性。例如 EGFR T790M 突变通过引入大的侧链基团“挤走”一代抑制剂；BCR-ABL T315I 突变也是经典案例。</li><br />
<li style="margin-bottom: 12px;"><strong>2. 旁路激活 (Bypass Signaling)：</strong> 当主要通路被阻断时，肿瘤细胞激活替代通路维持生长。例如 EGFR 突变肺癌使用奥希替尼治疗后，可能出现 <strong>MET 基因扩增</strong> 或 HER2 扩增，绕过 EGFR 继续激活 MAPK/PI3K 通路。</li><br />
<li style="margin-bottom: 0;"><strong>3. 表型转化 (Lineage Plasticity)：</strong> 肿瘤细胞改变其分化状态。最典型的例子是 EGFR 突变的非小细胞肺癌（NSCLC）在耐药后转化为<strong>小细胞肺癌（SCLC）</strong>，从而对原本的靶向药完全无效，需要改用化疗。</li><br />
</ul><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床对策：魔高一尺，道高一丈</h2><br />
<br />
<div style="overflow-x: auto; margin: 20px auto;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f1f5f9; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 20%;">癌种 (靶点)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #b91c1c; width: 30%;">典型耐药机制</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #16a34a; width: 50%;">克服策略 (下一代/联合)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">肺癌 (EGFR)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">T790M 突变 (约 50%)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">换用三代药物：<strong>[[奥希替尼]] (Osimertinib)</strong>，专门靶向 T790M。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">黑色素瘤 (BRAF)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">MAPK 旁路重激活</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">双靶联合：<strong>[[恩考芬尼]] + [[比美替尼]]</strong>，垂直阻断通路。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">慢性粒白血病 (BCR-ABL)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">T315I 突变</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">使用三代 TKI <strong>[[普纳替尼]] (Ponatinib)</strong> 或变构抑制剂 [[阿西米尼]]。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">结直肠癌 (BRAF)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">EGFR 反馈性上调</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">必须联合抗 EGFR 单抗 (如 [[西妥昔单抗]])。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献 [Academic Review]</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Garraway LA, Jänne PA. (2012).</strong> <em>Circumventing cancer drug resistance in the era of personalized medicine.</em> <strong>[[Cancer Discovery]]</strong>. <br><br />
<span style="color: #475569;">[点评]：经典的综述文章，详细阐述了靶向治疗耐药的三大核心机制：靶点改变、旁路激活和表型转化。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Vasan N, Baselga J, Hyman DM. (2019).</strong> <em>A view on drug resistance in cancer.</em> <strong>[[Nature]]</strong>. <br><br />
<span style="color: #475569;">[点评]：全面更新了对耐药性的理解，提出了多克隆耐药和治疗顺序的重要性。</span><br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
[3] <strong>Holohan C, et al. (2013).</strong> <em>Cancer drug resistance: an evolving paradigm.</em> <strong>[[Nature Reviews Cancer]]</strong>. <br><br />
<span style="color: #475569;">[点评]：从化疗到靶向治疗，系统性回顾了耐药机制的演变，并探讨了如何通过联合治疗克服 MDR。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
肿瘤药理学 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">上级学科</td><br />
<td style="padding: 10px 15px; color: #334155;">[[肿瘤学]] • 临床药理学</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">相关概念</td><br />
<td style="padding: 10px 15px; color: #334155;">[[肿瘤异质性]] • [[液体活检]] (用于检测耐药突变)</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">解决方案</td><br />
<td style="padding: 10px 15px; color: #334155;">[[联合疗法]] (Combination Therapy) • [[ADC 药物]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020